About EffRx

EffRx Pharmaceuticals SA is an innovative specialty pharmaceutical company focused on the development of novel therapeutic entities for a variety of orphan and specialty indications. Our goal is to improve the quality of life of patients with unmet medical needs.


The lead development product, EX404, targets polycystic ovary syndrome (PCOS) in adolescents. Additional product development pipeline targets include liver indications. EffRx is currently further expanding its product pipeline.



The product portfolio is led by already launched Binosto® for the treatment of postmenopausal osteoporosis. Binosto® (buffered effervescent alendronate 70mg for oral solution) is FDA approved. Currently Binosto® is marketed in the U.S. and by local distributors in other territories.

Partnering with Us

Our strategy relies on partnerships for shared commercial success. We directly develop and commercialize products for selected orphan indications, and partner with other pharmaceutical companies to develop and commercialize additional product candidates. We also partner with larger pharmaceutical companies that can utilize its delivery platform as an effective lifecycle management vehicle. We welcome you to find out more about partnering with us.


© 2016 EffRx Pharmaceuticals